Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
This new facility strengthens Latin America as a collaborative hub
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
Subscribe To Our Newsletter & Stay Updated
